Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-Herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.

Trial Profile

Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-Herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2013

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2012 Results from this trial were used to support approval of gabapentin enacarbil for the treatment of postherpetic neuralgia in the US.
    • 05 Oct 2009 Status changed from active, no longer recruiting to completed according to GlaxoSmithKline media release.
    • 05 Oct 2009 Top-line results reported in a GlaxoSmithKline media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top